References
- Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune
responses in aplastic anemia: molecular tracking of putatively
pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;
364:355-364.
- Issaragrisil S. Thai Aplastic Anemia Study Group. Epidemiology of
aplastic anemia in Thailand. Int J Hematol. 1999; 70:137-140.
- Young, Neal S. Aplastic anemia. The N Eng J Med. 2018;
379(17):1643-1656.
- Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia:
a prospective multicenter study. Haematologica. 2008; 93(4):518-523.
- Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a
prospective study of the effect of early marrow transplantation on
acute mortality. Blood. 1976;48 (1):63-70.
- Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of
immunosuppressive therapy in older patients with aplastic anemia. Ann
Intern Med. 1999; 130(3):193-201.
- Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and
clonal hematopoiesis in aplastic anemia. N Eng J Med. 2015;
373(1):35-47.
- Kim SY, Lee JW, Lee SE, et al. The characteristics and clinical
outcome of adult patients with aplastic anemia and abnormal
cytogenetics at diagnosis. Genes Chromosomes Cancer.
2010;49(9):844-850.
- Mikhailnova N, Sessarego M, Fugazza G, et al. Cytogenetic
abnormalities in patients with severe aplastic anemia. Haematologica.
1996; 81(5): 418-422.
- Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is
overexpressed in myelodysplastic syndrome and aplastic anemia and
predicts a response to immunosuppression in myelodysplastic syndrome.
Blood. 2002; 100(5):1570-1574.
- Narita A, Kojima S. Biomarkers for predicting clinical response to
immunosuppressive therapy in aplastic anemia. Int J Haematol. 2016;
104:153-158.
- Wang C, Zhang T, Wang Y, et al. The shortening telomere length of
T-lymphocytes maybe associated with hyper-function in severe aplastic
anemia. Mol Med Rep. 2018; 17(1):1015-1021.
- Tichelli A, Schrezenmeier H, Socie G, et al. A randomised controlled
study in patients with newly diagnosed severe aplastic anemia
receiving antithymocyte globulin (ATG), cyclosporine, with or without
G-CSF: a study of the SAA Working Party of the European Group for
Blood and Marrow transplantation. Blood.2011; 117(17):4434-4441.
- Tjon JM-L, de Groot MR, Sypkens Smit SMA, et al. Short-term efficacy
and safety of antithymocyte globulin treatment in elderly patients
with acquired aplastic anemia. Br J haematol. 2016; 180(3):459-462.
- Contejean A, Resche-Rigon M, Tamburini J, et al. Aplastic anemia in
the elderly: a nationwide survey on behalf of the French Reference
Center for Aplastic Anemia. Haematologica. 2018; 104(2):256-262.
- Killick SB, Cavenagh JD, Davies JK, et al. Low dose antithymocyte
globulin for the treatment of older patients with aplastic anemia.
Leuk Res. 2006; 30(12):1517-20.
- Hwang YY, Gill Harinder, Chan TSY, et al. Eltrombopag in the
management of aplastic anemia: real world experience in a non-trial
setting. Hematology.2018; 23(7): 399-404.
- Bacigalupo A. How I treat aplastic anemia. Blood. 2017; 129(11):
1428-1436.